Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New heparin dosing for obese heart surgery patients may cut bleeding risk

NCT ID NCT02675647

Disease control Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether using ideal body weight (instead of total body weight) to calculate heparin doses during heart-lung bypass reduces excessive bleeding in obese patients. Sixty obese adults scheduled for heart surgery were randomly assigned to receive heparin based on either ideal or total body weight. Researchers measured heparin levels, clotting time, bleeding, and transfusion needs to see if the new dosing is safer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Heparin
What this could lead to
If successful, this could lead to safer heparin dosing guidelines for obese patients undergoing heart surgery, reducing bleeding risks.
What could go wrong
This is a small, single-center Phase 4 study with only 60 participants, so results may not apply broadly. The approach may not significantly reduce bleeding or complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2015

Finished

Dec 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Obese patients (BMI ≥ 30 kg/m²) * Planned cardiac surgery under cardiopulmonary bypass * Coronary-artery bypass graft, or valve surgery) * Age ≥ 18 yo Exclusion criteria: * Allergy to heparin * Emergency surgical intervention * Redo surgery * Heart transplantation * Surgery for circulatory assistance * Pre-operative heparin use

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiac surgery are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiac surgery Cardiopulmonary bypass Obese patients (bmi ≥ 30 KG/m²)

Contacts and locations

Locations

  • Hôpitaux Universitaires de Strasbourg

    Strasbourg, 67091, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.